Antonio R. Anzueto (San Antonio, United States of America), Yuichiro Shindo (Nagoya, Japan)
The impact of smoking on community acquired pneumonia course and outcomes
Adamadia Liapikou (Athens, Greece), Adamadia Liapikou, Sotiria Makrodimitri, Konstantina Deskata, Matthew Katsaras, Christina Triantafillidou, Katerina Dimakou, Ioannis Dimitroulis, Michael Toumbis
|   |
Relationship between the use of inhaled steroids and early outcomes in community-acquired pneumonia
Adamadia Liapikou (Athens, Greece), Adamadia Liapikou, Sotiria Makrodimitri, Sofia Raftopoulou, Andreas Anastasopoulos, Panagiotis Petras, Micael Toumbis
| |
The impact of hyperglycemia on community-acquired pneumonia: A retrospective cohort study
Andreas Vestergaard Jensen (Roskilde, Denmark), Andreas Vestergaard Jensen, Gertrud Baunbæk-Knudsen, Stine Bang Andersen, Pelle Trier Petersen, Thomas Benfield, Daniel Faurholt-Jepsen, Gernot Rohde, Pernille Ravn
| |
Characteristics of pnemococcal community-acquired pneumonia presenting with respiratory failure
Leyre Serrano Fernandez (Bilbao (Bizkaia), Spain), Leyre Serrano Fernandez, Luis Alberto Ruiz, Pedro Pablo España, Ainhoa Gomez, Lorea Martinez-Indart, Marta Garcia, Amaia Aramburu, Alberto Capelastegui, Rafael Zalacain
| |
Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Kseniia Bielosludtseva (Dniepropetrovsk, Ukraine), Kseniia Bielosludtseva, Tetyana Pertseva, Tetyana Kireyeva
| |
YKL-40 and CCL18 predict mortality in patients hospitalised with community-acquired pneumonia; an observational analysis
Simone Spoorenberg (Nieuwegein, Netherlands), Simone Spoorenberg, Stefan Vestjens, Ger Rijkers, Bob Meek, Coline van Moorsel, Jan Grutters, Willem Jan Bos
| |
Critical review of the current management of pleural infection in a UK district general hospital. Applying the MIST II (multicentre intrapleural sepsis trial) evidence to our current practice
Benjamin Peirce (Cambridge, United Kingdom), Benjamin Peirce, Thomas Pulimood, Clare Harris
| |
Serum procalcitonin as a potential biomarker of surgery in parapneumonic pleural effusions
Arturo Cortes-Telles (Merida, Yucatan, Mexico), Arturo Cortes-Telles, Angel Emmanuel Vega-Sanchez, Jose Luis Che-Morales, Danielle Aimee Manjarrez-Martin, Gary Kosai Vargas-Mendoza
| |
Bacteremic vs. non-bacteremic pneumococcal pneumonia in immunocompetent patients: Predictive and prognostic factors
Rosanel Amaro Rodriguez (Premia de Dalt (Barcelona), Spain), Rosanel Amaro Rodriguez, Adamatia Liapikou, Catia Cilloniz, Albert Gabarrús, Framcesc Marco, Jacobo Sellarés, Eva Polverino, Javier Garau, Miquel Ferrer, Daniel M. Musher, Antoni Torres
| |
The risk factors of clinical practice for bacteremia in community- acquired pneumococcal pneumonia
Yasuyoshi Washio (Kurashiki, Japan), Yasuyoshi Washio, Akihiro Ito, Shogo Kumagai, Tadashi Ishida
| |
Predisposing factors for bacteremia in patients with community-acquired pneumonia and positive pneumococcal urinary antigen
Leyre Serrano Fernandez (Bilbao (Bizkaia), Spain), Leyre Serrano Fernandez, Rafael Zalacain, Alberto Capelastegi, Ainhoa Gomez, Lorea Martinez-Indart, Marta Garcia, Ane Uranga, Pedro Pablo España, Luis Alberto Ruiz
| |
Clinical impact of a prediction score for drug-resistance in community-onset pneumonia
Brandon Webb (Murray, United States of America), Brandon Webb, Jeff Sorensen, Herman Post, Peter Jones, Dominika Swistun, Al Jephson, Nathan Dean
| |
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa
Catia Cilloniz Campos (Barcelona, Spain), Catia Cilloniz Campos, Albert Gabarrus, Adamanthia Liapikou, Daniel Martinez, Michael Niederman, Antoni Torres
| |
Effect of giving antibiotics within 4 hours to patients with community-acquired pneumonia on mortality, length of stay and critical care admission
Olivia George (Manchester, United Kingdom), Olivia George, Ian Webster
| |
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Cornelis H. van Werkhoven (Utrecht, Netherlands), Cornelis H. van Werkhoven, Ewoudt M.W. van de Garde, Jan Jelrik Oosterheert, Douwe F. Postma, Marc J.M. Bonten
| |
Empiric penicillin monotherapy of CAP is not associated with increased mortality; experiences from the retrospective CAP-North cohort
Gertrud Baunbæk-Knudsen (Frederiksberg, Denmark), Gertrud Baunbæk-Knudsen, Andreas Vestergaard Jensen, Stine Andersen, Pelle Trier Petersen, Bjarne Ørskov Lindhardt, Christian von Plessen, Gernot Rohde, Pernille Ravn
| |
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Meng-Jer Hsieh (Taipei, Taiwan), Meng-Jer Hsieh, Chun-Chen Yu, Han-Chung Hu, Ying-Huang Thai
| |
Evolutionary trend of invasive pneumococcal disease according to serotypes
Maria Jose Galvez Medina (Madrid, Spain), Maria Jose Galvez Medina, Angela Ramos Pinedo, Jose Francisco Valverde Canovas, Elia Perez, Javier Solano, Mercedes Izquierdo, Nurua Echave, Marta Inmaculada Hernandez
| |